Moreover, combination of high-dose PD-L1 inhibitor and cisplatin in vivo is able to control and reduce tumor burden (p = 0.029), even if optimal timing and dosage are not yet defined [54,55,56]. This evidence concerns the gene CD274 and neoplasm.